Scripta Insights' Series B Success: $42M Raised to Revolutionize Pharmacy Navigation

In an ambitious show of growth and potential, Scripta Insights has successfully garnered $17 million in Series B funding, led by Aquiline, a private investment firm known for its focus on financial services and technology, bringing the company's total investment up to $42 million. The venture-backed digital health company specializes in pharmacy navigation solutions aimed at helping Americans, especially those on self-insured plans, understand and manage their prescription drug options to save money and improve health outcomes. Scripta's innovative products, Rx Navigator and Rx Monitor, allow plan members and sponsors to navigate the pharmacy landscape more effectively, thus reducing their drug costs and improving adherence rates. The capital from this round will be used to expand Scripta's reach in both the self-insured market and the health plan and Medicare Advantage markets. The investment comes as Scripta achieved over 100% revenue growth in 2024, affirming strong investor support amid a climate of increased scrutiny over prescription drug pricing. Not only has Scripta helped clients save over $29 million through approximately 78,000 prescription switches, but it has also strategically partnered with major benefits brokers and industry leaders to bolster its product offerings. Its innovative approach leverages proprietary clinical data and software to maximize savings opportunities, while also focusing on compliance and fiduciary duties linked to ERISA and ACA regulations.